Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)

BMJ Case Rep. 2020 Jun 7;13(6):e235117. doi: 10.1136/bcr-2020-235117.

Abstract

We report a case of euglycaemic diabetic ketoacidosis (EDKA) in a 43-year-old woman with type 2 diabetes mellitus who presented to the emergency department with problems of vomiting, cough, shortness of breath and generalised weakness after following a ketogenic diet for 2 weeks. Therapy with sodium glucose transport protein-2 empagliflozin had been started 2 months prior. Initial evaluation revealed high anion gap metabolic acidosis with blood glucose level of 169 mg/dL. Treatment for EDKA with fluid resuscitation, intravenous insulin and dextrose resolved her acidosis and symptoms in less than 24 hours. Empaglifozin was discontinued on discharge. This entity represents a diagnostic challenge since the differential diagnosis is broad with a potentially misleading clinical presentation that can result in delayed diagnosis and adverse outcomes including acute kidney injury, multiple electrolyte abnormalities, cerebral oedema, acute respiratory distress syndrome, shock and death.

Keywords: diabetes; unwanted effects / adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Benzhydryl Compounds* / administration & dosage
  • Benzhydryl Compounds* / adverse effects
  • Blood Glucose / analysis*
  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / therapy
  • Diabetic Ketoacidosis* / diagnosis
  • Diabetic Ketoacidosis* / etiology
  • Diabetic Ketoacidosis* / physiopathology
  • Diabetic Ketoacidosis* / therapy
  • Diagnosis, Differential
  • Diet, Ketogenic / adverse effects*
  • Female
  • Fluid Therapy
  • Glucosides* / administration & dosage
  • Glucosides* / adverse effects
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects
  • Insulin / administration & dosage*
  • Sodium-Glucose Transporter 2 / administration & dosage
  • Sodium-Glucose Transporter 2 / adverse effects
  • Time-to-Treatment

Substances

  • Benzhydryl Compounds
  • Blood Glucose
  • Glucosides
  • Hypoglycemic Agents
  • Insulin
  • Sodium-Glucose Transporter 2
  • empagliflozin